Kinome Scan - San Diego, California 92121

Kinome Scan is categorized under Commercial Biotechnical Research in San Diego, CA .

Business Name: Kinome Scan
Address: 11180 Roselle St # D, San Diego, California 92121
Phone Number: (858) 224-6900
Website Address: discoverx.com
Annual Revenue (USD): $1.000.000 to $2.499.999
Location Type: Branch
Employee Number: 1 to 4
Business Type: B2B (Business to Business)
Business Category: Commercial Biotechnical Research
SIC Code: 8731
NAICS Code: 6211112
Share This Business:
Related Businesses: Genestitute - San Diego, CA 92121
Abide Therapeutics - San Diego, CA 92121
Miltenyi Biotec Inc - San Diego, CA 92121
Ignyta - San Diego, CA 92121
Center For Aquaculture Tech - San Diego, CA 92121
Aires Pharmaceuticals Inc - San Diego, CA 92121
Oranox - San Diego, CA 92121
Rd Biosciences Inc - San Diego, CA 92121
Zenobia Therapeutics - San Diego, CA 92121
Arytha Biosciences LLC - San Diego, CA 92121
Abwiz Bio Inc - San Diego, CA 92121
Advantar Laboratories Inc - San Diego, CA 92121
Proacta Inc - San Diego, CA 92121
Anaptysbio Inc - San Diego, CA 92121
Nod Pharmaceuticals Inc - San Diego, CA 92121
Dermatrends Inc - San Diego, CA 92121
One World Lab Inc - San Diego, CA 92121
Motivatrx LLC - San Diego, CA 92121
Mapp Biopharmaceutical Inc - San Diego, CA 92121
Fate Therapeutics Inc - San Diego, CA 92121

The company Kinome Scan provides B2B services in the form of Commercial Biotechnical Research from its branch in California. 1 to 4 employees work for Kinome Scan, and the business now earns $1.000.000 to $2.499.999 per annum.

Kinome Scan was launched in 0 and is classified under SIC code and category 8731 , and NAICS number and grouping 6211112 . To contact Kinome Scan, please call with the phone number (858) 224-6900 or visit its branch at 11180 Roselle St # D in San Diego, California 92121.

The location of the branch can also be found using the coordinates 32.90597,-117.23113. Read more details about this business on the webpage discoverx.com or follow the company’s social media accounts, on Twitter and on Facebook.